Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 83.58

+1.8%

Nov 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1517)	3/22/2006 2:44:59 PM
From: Jibacoa	Read Replies (1) of 3722

NABI Is trying again to close some of its Nov.1 downgap. It opened today with an upgap and traded at 5.75 which its highest level since then. bigcharts.marketwatch.com Of course, it still has some room to go before it can close the Nov.1 gap and it is now above my buying range.<g> bigcharts.marketwatch.com Yesterday it announced that it will continue development of its Gram-positive program, led by StaphVAX and Altastaph They said that the decision was based on important conclusions from an outside advisory panel's review of StaphVAX PIII results, which revealed marked differences in the effectiveness of the lot of vaccine used in this study compared to the lot used in the previous Phase III. On Nov.1 was when it announced that the study had failed to meet its primary endpoint, but since the results were not consistent with previous positive data for StaphVAX, the company started an investigation plan and formed an outside advisory panel. In collaboration with the panel, Nabi reached two conclusions related to the future development of StaphVAX and Altastaph: 1. The quality or functional characteristics of the antibodies generated by the vaccine used in the confirmatory clinical study was inferior to those antibodies generated by vaccine lots used in previous and subsequent clinical studies. 2. Medical factors associated with kidney disease in dialysis patients impaired their immune response to the vaccine. When considered in combination with an increase in the virulence of the bacteria, these factors also contributed to the observed lack of protection in this study population. NABI's CEO stated, "Today's announcement marks a new beginning for our Gram-positive program, which is much enhanced by the knowledge we've gained about the bacteria and immune response. Moving forward, we have a clear development pathway on which to readily advance our vaccine and antibody products toward commercialization." biz.yahoo.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next